Get access to our best features
Get access to our best features
Published 1 year ago

Managing T-DXd Adverse Events in the Real World

Summary by Ground News
Trastuzumab deruxtecan (T-DXd) has been on the market since 2019 for breast cancer. Expanding use of this drug has led to growing awareness among oncologists. Nausea and vomiting are among the most common low-grade adverse events.

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)